-
GenScript Biotechnology Announces 2020 Annual Results
Time of Update: 2021-07-13
This is mainly due to: (i) investing in new coronary pneumonia-related projects and other challenging new research and development projects, which have greatly improved our market competitiveness and production efficiency; (ii) clinical trial expenses and preclinical research costs (especially cell Therapeutics segment) increased; and (iii) R&D staff's remuneration package (including share-based payments) increased .
-
Anti-LAG-3 antibody Relatlimab combined with Odivo bring benefits to melanoma patients
Time of Update: 2021-07-13
March 25, 2021, Bristol-Myers Squibb (NYSE: BMY) announced (CA224-047) preliminary results of a Phase 2/3 clinical study RELATIVITY-047, which was designed to evaluate and Ou Diwo ® (Wu Li You satisfied mAb) monotherapy compared with the fixed-dose combination of anti-LAG-3 antibody and Ou Diwo relatlimab ® treatment for previously untreated, unresectable or metastatic melanoma patients .
-
BeiGene announces the appointment of Wang Aijun as its new chief financial officer
Time of Update: 2021-07-13
Aijun Wang said: “I am honored to be the Chief Financial Officer of BeiGene, and together with the company to revolutionize the biotechnology industry by creating influential, affordable and accessible drugs for more patients around the world .
-
AffaMed Therapeutics announces the completion of more than $170 million in Series B financing
Time of Update: 2021-07-12
AffaMed Therapeutics, a clinical-stage innovative biopharmaceutical company dedicated to meeting the needs of patients with global ophthalmology, neurological and psychiatric diseases, announced the completion of more than $170 million in Series B financing .
-
Major personnel adjustment of Medtronic: Brooke Story, President of Gastric Therapy, resigns to join BD
Time of Update: 2021-07-12
On March 30, according to foreign media such as Fierce Pharma, Brooke Story, president of Medtronic's pelvic health and gastric treatment, announced his resignation and will join BD as the global president of integrated diagnostic solutions.
-
Boehringer Ingelheim and Neptune jointly create a closed loop of chronic disease management services
Time of Update: 2021-07-12
The project aims to cultivate a staff talent system for chain pharmacies, build a chronic disease management team, help pharmacists improve their professional capabilities, provide further learning opportunities and a broad development platform, so as to provide patients with better pharmaceutical services and a more comprehensive health awareness And a higher quality of life .
-
Innovent's PI3Kδ inhibitor Parsaclisib was approved by the National Food and Drug Administration as a breakthrough therapeutic drug for the treatment of relapsed or refractory follicular lymphoma
Time of Update: 2021-07-12
At the 62nd American Hematology Annual Meeting (ASH) held in 2020, Incyte's American partner, Incyte, reported a clinical study data of Parsaclisib in the treatment of relapsed/refractory follicular lymphoma (research Code: CITADEL-203, Abstract 2935) .
-
Gao Tejia’s new shareholder dispute, Cai Dajian’s ex-wife Jin Huili is out
Time of Update: 2021-07-12
According to the announcement, Jinhuili controlled Sunshine Jiarun, Jiaxing Herun, Susuda and the other two shareholders of Gaotejia, Shenzhen Peninsula Bay Investment Partnership, and Xiamen Gaotejia Elite Investment Partnership, which are equivalent to Delai Electric Signed an equity transfer agreement and transferred a total of 59.
-
WeDoctor officially submits IPO prospectus, revenue of 1.8 billion yuan in 2020
Time of Update: 2021-07-12
Digital medical service platform WeDoctor Holdings formally submitted a listing application to the main board of the Hong Kong Stock Exchange on the evening of April 1 .
In 2020, medical service revenue is 706 million yuan, accounting for 38.
-
Servier was fined more than 10 million yuan for the drug accident. How did the drug turn from treating the disease to harming others?
Time of Update: 2021-07-12
The verdict stated that Servier had discovered that the drug would cause serious damage to heart valves many years ago, but the company did not take corresponding measures.
-
Some people retired from the rapids and some were investigated for violations of discipline.
Time of Update: 2021-07-12
Repeated coaching changes-Chinese Medicine On February 2, China Pharmaceuticals announced that due to work adjustments, Gao Yuwen had applied for the resignation of the company's chairman (legal representative), directors and relevant positions of the special committees of the board of directors .
-
Golly announces the upgrade of R&D investment in tumor lipid metabolism and oral checkpoint inhibitors
Time of Update: 2021-07-12
As a new generation of oral fatty acid synthase small molecule inhibitors, ASC60 is expected to be combined with other therapies to treat a variety of solid tumors .
-
Zhang Huawei, chairman of Weigao shares, resigns
Time of Update: 2021-07-12
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors, chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years .
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021 .
-
High-value consumables are collected and prosperous, and Minimally Invasive Medical has a huge loss of 1.2 billion in 4 years of overdraft profits last year
Time of Update: 2021-07-12
During the reporting period, its cardiovascular intervention product business, orthopedic medical device business, and heart rhythm management business accounted for the bulk of its revenue, which were 22.
-
Kazia grants the license of paxalisib in Greater China to Simcere
Time of Update: 2021-07-12
Kazia Therapeutics Limited, a drug development company focused on cancer treatment, announced that it has signed a license agreement with Simcere Pharmaceutical Group Co.
Highlights: Simcere Pharmaceuticals will be responsible for the clinical development, drug registration and commercialization of paxalisib in Greater China (Mainland China, Hong Kong, Macau and Taiwan) .
-
The annual report of Huaxi Biology will increase revenue without increasing profits. Does the road to medical beauty rely on hyaluronic acid or Li Jiaqi?
Time of Update: 2021-07-12
"Quadi" brand is the high-end product line of Huaxi Bio's functional skin care business.
In addition to functional skin care products, Huaxi Biology also has a raw material product business and a medical terminal business .
-
Fujifilm officially acquired Hitachi Medical Imaging, providing one-stop solutions
Time of Update: 2021-07-12
In recent years, medical institutions have hoped that suppliers can provide comprehensive solutions that directly contribute to their operations and management, and they need to combine various products .
-
Nuocheng Jianhua releases 2020 annual performance report and company progress
Time of Update: 2021-07-12
Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) released the 2020 annual performance report and company progress as of December 31, 2020 on March 26 . Dr. Cui Jisong, co-founder, chairman
-
Genting Xinyao Announces China National Medical Products Administration Approves Trodelvy's New Use Clinical Trial Application
Time of Update: 2021-07-12
Everest Medicines (Everest Medicines), a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to meeting the unmet medical needs of Greater Ch
-
Luye Pharma and JD Health jointly hold bipolar disorder science lecture
Time of Update: 2021-07-12
"Unlike unipolar depression, patients with bipolar disorders also have a history of manic episodes, sometimes with high moods and sometimes low depressions, showing completely different states at different stages .
"Precision" treatment based on the patient's personal characteristics is the "artistic of clinical treatment" mentioned by Professor Zhang Yan .
